BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) (“Karyopharm,” the “Company,” “we” and “our”), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Cyteir Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors.

Oculis S.A. announces the further strengthening of the Company’s executive leadership team with the appointment of Dr. Bastian Dehmel as global Chief Development Officer.

QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets, announced an expansion of its leadership team to strengthen expertise in regulatory affairs, clinical affairs and operations, and global supply management.

Ovid Therapeutics announced that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol. Under the agreement, Healx plans to investigate the compound as part of a potential combination therapy for Fragile X syndrome, as well as a treatment for other indications.

Frontier Medicines Corporation announced Piro Lito, M.D., Ph.D., associate member and attending physician at Memorial Sloan Kettering Cancer Center, has joined its scientific advisory board.

Gain Therapeutics, Inc. today presented new pre-clinical data from its Gaucher Disease (GD) program.

CereVasc, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients with normal pressure hydrocephalus (NPH).

Sensifree LTD, a medical device company developing advanced patient monitoring solutions, announced the launch of a joint development program supported by the BIRD Foundation, with Cleveland Clinic.

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market.